Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

The healthcare sector is dominated by massive players, but few are as influential as UnitedHealth Group Incorporated UNH and ...

CVS Health CVS has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...